Amid all the posters, plenaries, and presentations of the nation’s biggest neurology conference, one story stood out: Spinal muscular atrophy, once an untreatable condition, has become the staging ground for one of the drug industry’s most intense competitions.
This year’s American Academy of Neurology meeting offered plenty of answers about SMA treatments from Novartis (NVS), Roche (RHHBY), and Biogen (BIIB) — but left enough questions to stir debate over just which therapy will lead the SMA market in years to come.
Here’s your guide to what we learned — and didn’t learn — about the future of treating SMA.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect